Ernest Borden, MD, Oncology, Cleveland, OH, Cleveland Clinic

ErnestCBordenMD

Oncology Cleveland, OH

Dr. Ernest C. Borden, M.D. serves as Vice Chairman of Taussig Cancer Center. Dr. Borden serves as Director of the Center for Drug Discovery and Development of Taussig Cancer Center at Cleveland Clinic Foundation. He is a staff member in the Department of

Are you Dr. Borden?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 57 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Ernest Borden, MD is an oncologist in Cleveland, Ohio. He is currently licensed to practice medicine in Ohio and North Carolina. He is affiliated with Cleveland Clinic and is a Dr. Ernest C. Borden at M.D. serves as Vice Chairman of Taussig Cancer Center. Dr. Borden serves as Director of the Center for Drug Discovery and Development of Taussig Cancer Center at Cleveland Clinic Foundation. He is a staff member in the Department of.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Medical Oncology, 1970 - 1973
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1967 - 1968
  • Duke University Hospital
    Duke University HospitalInternship, Internal Medicine, 1966 - 1967
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1966

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1999 - 2015
  • NC State Medical License
    NC State Medical License 1966 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • SHP1 Targeted Inhibition By Stibogluconate For MelanomaNational Cancer Institute2007
  • Phase I Evaluation Of Sodium StibogluiconateNational Center For Research Resources2006
  • Shpi Targeted Inhibition By Stibogluconate For MelanomaNational Cancer Institute2006
  • Clinical And Cellular Effects Of InterferonNational Center For Research Resources2004–2005
  • Increasing Effects Of Interferons For MelanomaNational Cancer Institute2004–2005
  • Clinical And Cellular Effects Of Interferon Alfa 1National Cancer Institute2004–2005
  • Increasing Effects Of Interferons For MelanomaNational Cancer Institute2002–2003
  • Clinical And Cellular Effects Of Interferon Alfa 1National Cancer Institute2001–2003
  • Cancer And Leukemia Group BNational Cancer Institute1995–1997
  • Phase 1a,1b Evaluation Of IL-6 In Patients With Advanced Malignant DiseaseNational Center For Research Resources1995
  • Phase I/Ii--Clinical Evaluation Of Biological ResponseDivision Of Cancer Treatment1994
  • Phase I/II - Clinical Evaluation Of Biological ResponseDivision Of Cancer Treatment1992–1993
  • Physician Scientist Training In Cancer MedicineNational Cancer Institute1988–1990
  • Oncology Education--Summer Research And PreventionNational Cancer Institute1988–1990
  • Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1988–1990
  • Phase IA And IB Trials Of Combinations Of InterferonDivision Of Cancer Treatment1985–1988
  • Cancer Education ProgramNational Cancer Institute1987
  • Clinical Evaluation Of Biological Response ModifiersDivision Of Cancer Treatment1985–1987
  • Professional Oncology Education ProgramNational Cancer Institute1985–1986

Professional Memberships

Hospital Affiliations